[New treatments for cutaneous lupus]

Area of Science:

• Dermatology
• Rheumatology
• Immunology

Background:

• Cutaneous lupus erythematosus (CLE) is a skin condition that can occur independently or alongside systemic lupus erythematosus (SLE).
• Current treatment strategies for CLE are not standardized and depend on disease severity and systemic involvement.
• Hydroxychloroquine and other synthetic antimalarials form the basis of current CLE management.

Purpose of the Study:

• To review the current landscape of cutaneous lupus treatments.
• To highlight recent advancements and emerging therapies for CLE.
• To discuss the potential role of anifrolumab in managing skin manifestations of lupus.

Main Methods:

• Review of current literature on cutaneous lupus treatments.
• Analysis of recent clinical trial data for novel therapeutic agents.
• Evaluation of European marketing authorization for anifrolumab in SLE.

Main Results:

• Anifrolumab received European marketing authorization for systemic lupus in 2022.
• Anifrolumab has demonstrated promising results in addressing skin involvement in lupus patients.
• Despite promising developments, some new molecules have yielded both positive and negative outcomes.

Conclusions:

• Anifrolumab represents a significant advancement in lupus treatment, with notable efficacy in cutaneous manifestations.
• Further research is warranted to fully elucidate the long-term benefits and optimal use of anifrolumab in CLE.
• The evolving therapeutic landscape offers new hope for patients with cutaneous lupus, moving beyond traditional antimalarial therapies.